N@N

Kendall Law Group Investigates ZymoGenetics, Inc. Acquisition for Shareholders

^{Published on 2010-09-08 06:42:45 - Market Wire}
 

DALLAS--([ BUSINESS WIRE ])--[ Kendall Law Group ], a national securities firm led by a former federal judge with attorneys that include a former U.S. Attorney, is investigating ZymoGenetics, Inc. (NASDAQ: ZGEN) for shareholders in connection with the proposed acquisition by the Bristol-Myers Squibb Company. The national securities firma™s investigation seeks to determine whether ZymoGenetics and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a ZymoGenetics shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [ skendall@kendalllawgroup.com ].

On September 7, 2010 the companies announced that the companies have entered into a definitive merger agreement under which ZymoGenetics would be acquired by Bristol-Myers Squibb in a transaction valued at approximately $735 million net of cash acquired. Under the terms of the agreement, ZymoGenetics stockholders will receive $9.75 in cash for each share of ZymoGenetics/ZGEN common stock held. The firma™s investigation seeks to discover whether the transaction properly values the company.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.